LOVENOX®-- Patient Information
sanofi-aventis homepage sanofi-aventis homepage  
KNOW LOVENOX®

My Doctor Has

Prescribed LOVENOX®

Your doctor has prescribed LOVENOX® to help reduce your risk of developing deep vein thrombosis, also known as DVT blood clots. LOVENOX® alters the blood’s normal clotting process, so clots can’t form as easily, and neither can a potentially fatal pulmonary embolism.

Learn step-by-step instructions on how to self-inject LOVENOX®, and read about possible side effects. And remember, if you have any questions about LOVENOX® or DVT blood clots, please speak with your doctor or call the Patient Hotline at 1-800-633-1610.

At Home with LOVENOX®

This video provides helpful instruction on how to self-inject LOVENOX® at home.

You need a Flash Player in order to view the full content of the current page. Please download the latest version of Flash Plug-in from the Macromedia Flash Player Download Center.

View Video Transcripts

INDICATIONS

LOVENOX® is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:

  • in patients undergoing abdominal surgery who are at risk for thromboembolic complications;
  • in patients undergoing hip-replacement surgery, during and following hospitalization;
  • in patients undergoing knee-replacement surgery;
  • in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.

LOVENOX® injection is indicated for:

  • the inpatient treatment of acute deep vein thrombosis, with or without pulmonary embolism, when administered in conjunction with warfarin sodium;
  • the outpatient treatment of acute deep vein thrombosis, without pulmonary embolism, when administered in conjunction with warfarin sodium.
Important Safety Information

Certain procedures, called "epidural/spinal anesthesia" and "spinal puncture," may be used as a normal part of hospitalization. Patients requiring these procedures while being treated with LOVENOX® or other low-molecular-weight heparins are at risk of developing a blood clot in or around the spine. This condition may result in long-term or permanent paralysis.

LOVENOX® is not the same as "unfractionated heparin" or other drugs called "low-molecular-weight heparins." Therefore, these drugs cannot be used interchangeably with LOVENOX®.

LOVENOX® can alter the blood’s ability to clot. Patients treated with LOVENOX®, who also have conditions affecting the clotting system, must be carefully monitored by their physician. Adjusting the dose of LOVENOX® may be necessary for patients who have certain forms of kidney disease. All patients receiving LOVENOX®, as well as other anticoagulants, should be carefully monitored for bleeding by their physician. Bleeding can occur at any site with LOVENOX® use.

Platelet drops, known as "thrombocytopenia," can occur with LOVENOX® use. Cases of a related condition called "heparin-induced thrombocytopenia" have been observed in clinical practice. If you have had this condition, you must notify your healthcare professional. Your physician may perform blood tests to monitor for the occurrence of any drop in platelet count.

The use of LOVENOX® has not been adequately studied in pregnant women with artificial (mechanical) heart valves.

LOVENOX® should not be used in patients with an allergy or sensitivity reaction to the active ingredient called enoxaparin sodium, heparin, or pork products, and in patients with active major bleeding.

Common side effects include mild local reactions or irritation at the site of injection, pain, bruising, and redness of skin.

For specific questions about your health, you should always consult your physician or a qualified healthcare professional who is responsible for your care.

Please see Full Prescribing Information including boxed WARNING for additional important information.